NCT06777628View on ClinicalTrials.gov

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

October 15, 2026

Study Completion Date

October 15, 2028

Conditions
Liver Cancer, Adult
Interventions
DRUG

Immunochemotherapy combined with antiangiogenic

Immunochemotherapy combined with antiangiogenic

Trial Locations (1)

40138

RECRUITING

IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Bologna

All Listed Sponsors
lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER